{
  "meta": {
    "title": "Adrenal",
    "url": "https://brainandscalpel.vercel.app/adrenal-aeba86c6.html",
    "scrapedAt": "2025-11-29T18:33:51.735Z"
  },
  "questions": [
    {
      "id": 3685,
      "choices": [
        {
          "id": 14719,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
        },
        {
          "id": 14720,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
        },
        {
          "id": 14721,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></span></span></p>"
        },
        {
          "id": 14722,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rosiglitazone</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old patient with Type 2 diabetes mellitus is being evaluated for potential adjustments to their diabetes management plan. The patient&#39;s current regimen includes metformin and lifestyle modifications. However, recent glycemic control has been suboptimal, and the healthcare provider is considering adding an additional medication to enhance insulin secretion, aiming to achieve better glucose control. Which of the following antidiabetic drugs act by increasing the secretion of insulin, making it a suitable addition to this patient&#39;s diabetes management plan?</span></span></span></p>",
      "unique_key": "Q7165833",
      "question_audio": null,
      "question_video": null,
      "map_id": 36094,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Exenatide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>glucagon-like peptide-1 (GLP-1) receptor agonist.</strong> It works by<strong> increasing insulin secretion </strong>in a glucose-dependent manner, meaning it stimulates <strong>insulin release when blood glucose levels are high.</strong> Additionally, <strong>exenatide slows gastric emptying, suppresses appetite, and inhibits inappropriate post-meal glucagon release,</strong> all of which contribute to<strong> lowering blood glucose</strong> levels. Because of its mechanism of <strong>enhancing insulin secretion</strong> and other <strong>beneficial effects on glucose control, exenatide</strong> is a suitable addition for a patient with<strong> Type 2 diabetes </strong>looking to <strong>improve glycemic control </strong>beyond what has been achieved <strong>with</strong> <strong>metformin and lifestyle modifications.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pramlintide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is an <strong>amylin analogu</strong>e that <strong>mimics the natural hormone amylin</strong>. Pramlintide <strong>slows gastric emptying,</strong> <strong>reduces postprandial glucagon secretion,</strong> and <strong>promotes satiety</strong>, leading to <strong>decreased caloric intake</strong>. However, it<strong> does not</strong> directly <strong>increase insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a <strong>biguanide,</strong> which is already part of the patient&#39;s regimen. Metformin works mainly by <strong>decreasing</strong> <strong>hepatic glucose production </strong>and improving<strong> insulin sensitivity</strong> but <strong>does not</strong> <strong>increase insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Rosiglitazone</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It belongs to the <strong>thiazolidinedione</strong> class of drugs, which work by<strong> increasing insulin sensitivity</strong> rather than directly<strong> stimulating insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ANTI-DIABETIC DRUGS THAT ACT BY INCREASING THE SECRETION OF INSULIN:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture4.jpg\" style=\"height:744px; width:1000px\" /></span></span></strong></p>",
      "correct_choice_id": 14721,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3636,
      "choices": [
        {
          "id": 14523,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypogonadotropic hypogonadism</span></span></span></p>"
        },
        {
          "id": 14524,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Premature ovarian failure</span></span></span></p>"
        },
        {
          "id": 14525,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperprolactinemia</span></span></span></p>"
        },
        {
          "id": 14526,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polycystic ovarian disease</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old female presented to the hospital with infertility. After thorough examination and relevant investigations, she was prescribed bromocriptine by the gynecologist. Most likely reason of her infertility is.</span></span></span></p>",
      "unique_key": "Q9742322",
      "question_audio": null,
      "question_video": null,
      "map_id": 36097,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Hyperprolactinemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bromocriptine</strong> is a <strong>dopamine agonist</strong> that is primarily used to treat conditions associated with <strong>hyperprolactinemia.</strong> <strong>Hyperprolactinemia</strong> is a condition characterized by an<strong> elevated level of prolactin</strong> in the blood. Prolactin is a hormone <strong>produced by</strong> the<strong> pituitary gland</strong> that, in <strong>high levels</strong>, can <strong>suppress </strong>the production of <strong>gonadotropin-releasing hormone (GnRH), </strong>leading to <strong>reduced</strong> <strong>secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH)</strong>. This suppression can result in <strong>menstrual irregularities</strong> and <strong>anovulation</strong>, making conception difficult. By<strong> lowering prolactin levels</strong>, <strong>bromocriptine</strong> can<strong> restore ovulation and menstrual</strong> <strong>regularity, </strong>thus addressing the<strong> infertility issue</strong> in patients with <strong>hyperprolactinemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypogonadotropic hypogonadism</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> refers to a condition caused by <strong>insufficient production of gonadotropin-releasing</strong> <strong>hormone (GnRH)</strong> by the <strong>hypothalamus,</strong> leading to<strong> low levels of LH and FSH </strong>and, consequently,<strong> impaired gonadal function.</strong> Treatment typically involves <strong>hormone replacement </strong>rather than <strong>dopamine agonists.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Premature ovarian failure</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is characterized by the<strong> loss of normal ovarian function </strong>before the age of <strong>40</strong>. Women with this condition have <strong>low estrogen levels</strong> and often <strong>elevated gonadotropin levels</strong>. Treatment may include<strong> hormone replacement therapy,</strong> but <strong>not specifically bromocriptine.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Polycystic ovarian disease (PCOD)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, also known as polycystic ovary syndrome (PCOS), is a <strong>hormonal disorder </strong>causing <strong>enlarged ovaries with small cysts on the outer edges</strong>. The<strong> treatment </strong>focuses on managing symptoms and may include<strong> lifestyle</strong> <strong>changes, insulin sensitizers, and fertility treatments</strong>, but<strong> not</strong> typically<strong> bromocriptine unless hyperprolactinemia </strong>is also present.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hyperprolactinemia,</strong> characterized by <strong>elevated levels of prolactin, </strong>can cause <strong>infertility </strong>due to its <strong>suppression </strong>of important reproductive hormones like <strong>GnRH, FSH, and LH</strong>. Bromocriptine helps<strong> restore fertility </strong>by <strong>lowering prolactin levels.</strong></span></span> <span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></p>",
      "correct_choice_id": 14525,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3947,
      "choices": [
        {
          "id": 15767,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2 and 4 are correct.</span></span></span></p>"
        },
        {
          "id": 15768,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2 and 3 are correct.</span></span></span></p>"
        },
        {
          "id": 15769,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only 4 is correct.</span></span></span></p>"
        },
        {
          "id": 15770,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are correct.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following are adverse effects of SGLT2 inhibitors? </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol start=\"1\" style=\"list-style-type:lower-alpha\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoacidosis </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urosepsis </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fournier&#39;s gangrene </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Angioedema </span></span></span></li>\r\n</ol>",
      "unique_key": "Q7736644",
      "question_audio": null,
      "question_video": null,
      "map_id": 36095,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. 1, 2 and 3 are correct. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium glucose co-transporter-2 inhibitors (SGLT-2 inhibitors):</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Glucose is freely filtered by the renal glomeruli </strong>and is <strong>reabsorbed in the proximal tubules</strong> by the action of <strong>sodium-glucose transporters (SGLTs). </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium-glucose transporter 2<strong> (SGLT2) </strong>accounts for <strong>90% of glucose reabsorption</strong>, and its <strong>inhibition causes glycosuria and</strong> <strong>lowers glucose levels </strong>in patients with <strong>type 2 diabetes. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>SGLT2 inhibitors lower glucose level</strong>s by<strong> changing the renal threshold</strong> and <strong>not by insulin action.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin, </strong>all oral medications, are approved for <strong>clinical use</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Side effects of SGLT2 inhibitors </strong>include <strong>ketoacidosis, urosepsis, Fournier&#39;s gangrene, increased incidence of UTI and</strong> <strong>genital infections.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note - Angioedema (Option d) is not commonly associated with SGLT2 inhibitors</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>SGLT2 inhibitors</strong> are effective for<strong> lowering glucose levels </strong>in patients with <strong>type 2 diabetes,</strong> they can lead to serious side effects such as <strong>ketoacidosis, urosepsis, and Fournier&#39;s gangrene. </strong>It is important for<strong> healthcare </strong>providers to <strong>monitor for signs </strong>of these conditions and for patients to be <strong>aware of their symptoms.</strong></span></span></span></span></span></span></p>",
      "correct_choice_id": 15768,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3963,
      "choices": [
        {
          "id": 15831,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rosiglitazone</span></span></span></p>"
        },
        {
          "id": 15832,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Repaglinide</span></span></span></p>"
        },
        {
          "id": 15833,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></span></p>"
        },
        {
          "id": 15834,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drug&rsquo;s act by increasing the secretion of insulin except? </span></span></span></p>",
      "unique_key": "Q4671072",
      "question_audio": null,
      "question_video": null,
      "map_id": 36099,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Rosiglitazone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Rosiglitazone</strong> is a member of the <strong>thiazolidinediones class of drugs, </strong>which act by<strong> stimulating peroxisome proliferator-activated</strong> <strong>receptor gamma (PPAR-gamma).</strong> This action primarily <strong>increases insulin sensitivity in peripheral tissue </strong>and <strong>does not</strong> directly <strong>increase the secretion of insulin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Repaglinide</strong> is a<strong> meglitinide</strong> which <strong>acts as a potassium ATP (K_ATP) </strong>channel blocker on pancreatic beta cells, directly <strong>stimulating</strong> the<strong> secretion of insulin. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Exenatide</strong> is an <strong>incretin mimetic, </strong>which mimics the action of<strong> incretins like GLP-1 to increase insulin secretion</strong> in response to<strong> high blood glucose levels. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Sitagliptin</strong> is a <strong>dipeptidyl peptidase-4 (DPP-4) inhibitor</strong> that prevents the<strong> breakdown of incretins,</strong> thereby prolonging their action and leading to<strong> increased insulin secretion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture23.jpg\" style=\"height:642px; width:1000px\" /></p>",
      "correct_choice_id": 15831,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3949,
      "choices": [
        {
          "id": 15775,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Weight loss</span></span></span></p>"
        },
        {
          "id": 15776,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polyuria</span></span></span></p>"
        },
        {
          "id": 15777,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased incidence of urinary tract infections</span></span></span></p>"
        },
        {
          "id": 15778,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is an adverse effect of dapagliflozin?</span></span></span></p>",
      "unique_key": "Q8634615",
      "question_audio": null,
      "question_video": null,
      "map_id": 36096,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. All the above</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dapagliflozin</strong> is an<strong> SGLT-2 inhibitor</strong> used in the treatment of <strong>type 2 diabetes mellitus.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Glucose </strong>is <strong>freely filtered by the renal glomeruli</strong>. <strong>Sodium-glucose transporter 2 (SGLT2) </strong>accounts for<strong> 90% of glucose</strong> <strong>reabsorption</strong>, and its <strong>inhibition</strong> causes<strong> glycosuria and lowers glucose levels</strong> in patients with <strong>type 2 diabetes. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>SGLT2 inhibitors</strong> <strong>lower glucose levels</strong> by <strong>changing the renal threshold </strong>and not by insulin action.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Due to <strong>increased excretion of glucose in the urine,</strong> dapagliflozin increases the<strong> risk of UTI. </strong>Further, there is<strong> polyuria and</strong> <strong>weight loss with the use of this drug.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other<strong> adverse effects of SGLT2 inhibitors include ketoacidosis, urosepsis, Fournier&#39;s gangrene, and increased incidence of UTI and genital tract infections.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dapagliflozin </strong>and<strong> other SGLT2 inhibitors are effective </strong>in <strong>lowering blood glucose levels in type 2 diabetes patients </strong>but can lead to several adverse effects such as<strong> weight loss, polyuria, and an increased risk of UTIs.</strong> <strong>Patients and healthcare providers</strong> should be aware of these<strong> potential side effects</strong> and<strong> manage them </strong>through <strong>regular monitoring and supportive care.</strong></span></span></span></p>",
      "correct_choice_id": 15778,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3738,
      "choices": [
        {
          "id": 14931,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sucrose</span></span></span></p>"
        },
        {
          "id": 14932,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Galactose </span></span></span></p>"
        },
        {
          "id": 14933,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glucose</span></span></span></p>"
        },
        {
          "id": 14934,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Starch</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is receiving insulin and acarbose for diabetes mellitus and developed hypoglycemia. Which of the following should be used for treatment of hypoglycemia in this patient?</span></span></span></p>",
      "unique_key": "Q5030756",
      "question_audio": null,
      "question_video": null,
      "map_id": 36098,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Glucose</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the scenario where a patient is <strong>treated with insulin and acarbose and subsequently develops hypoglycemia</strong>, the immediate treatment should involve<strong> administering glucose directly</strong>. Acarbose is an <strong>alpha-glucosidase inhibitor</strong>, which impedes the<strong> breakdown and absorption of complex carbohydrates </strong>in the intestine. Therefore, <strong>treating hypoglycemia with complex carbohydrates like sucrose or polysaccharides (starch) would not </strong>be effective because<strong> acarbose </strong>would<strong> prevent </strong>their <strong>rapid conversion to glucose. </strong>Simple<strong> </strong>carbohydrates like <strong>glucose</strong>, which <strong>do not</strong> require <strong>intestinal digestion</strong>, are the optimal choice as they can be quickly<strong> absorbed into the bloodstream </strong>to <strong>counteract hypoglycemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Sucrose:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Not suitable</strong> for quick correction of<strong> hypoglycemia </strong>in this context because<strong> acarbose inhibits the enzyme </strong>needed to <strong>break down sucrose</strong> into<strong> glucose and fructose, </strong>thereby delaying its <strong>action in raising blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Galactose:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While <strong>galactose is a simple sugar</strong>, it is <strong>not </strong>the preferred <strong>treatment for hypoglycemia</strong> as it is <strong>not </strong>as efficiently utilized by the <strong>body as glucose.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Starch:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Starch</strong> is a<strong> complex carbohydrate</strong> that would be<strong> broken down into glucose</strong> much <strong>more slowly</strong>, especially in the presence of <strong>acarbose,</strong> making it <strong>ineffective</strong> for the <strong>immediate treatment of hypoglycemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In cases of<strong> hypoglycemia,</strong> especially in patients using <strong>alpha-glucosidase inhibitors like acarbose</strong>, <strong>direct administration of glucose</strong> is <strong>recommended</strong> as it provides the<strong> fastest and most effective </strong>means of <strong>restoring blood sugar levels</strong> <strong>without </strong>the need for <strong>enzymatic</strong> <strong>digestion.</strong></span></span></span></p>",
      "correct_choice_id": 14933,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}